Canaccord Genuity analyst Mark Massaro maintained a Buy rating on GenMark (NASDAQ: GNMK) today and set a price target of $9. The company’s shares closed yesterday at $6.30.
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 16.4% and a 62.5% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Orasure Technologies, Idexx Laboratories, and Exact Sciences.
GenMark has an analyst consensus of Strong Buy, with a price target consensus of $10.33.
See today’s analyst top recommended stocks >>
Based on GenMark’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $11.42 million. In comparison, last year the company had a GAAP net loss of $17.99 million.
Based on the recent corporate insider activity of 105 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GenMark Diagnostics, Inc. is a molecular diagnostics company, which engages in the development and commercialization of proprietary eSensor electrochemical detection technology. It also manufactures, sells, and supports instruments and molecular tests. The company was founded by Jon Faiz Kayyem on February 12, 2010 and is headquartered in Carlsbad, CA.
